Browsing: Therapeutics

Up to $35 million from the Gates Foundation will support ProFound’s use of its platform, datasets, and algorithms to identify new drug targets and biomarkers for preeclampsia and eclampsia

Axsome Therapeutics (NASDAQ: AXSM), a biotech company, has performed fairly well this year. The company’s shares are up 16% versus the S&P 500’s 11%. Could the stock rise even higher? Wall Street certainly thinks so. Axsome Therapeutics’ average price target (according to Yahoo! Finance) of $285.42 implies about a 37% upside from its current level.…

Silence Therapeutics and AbCellera launched respective common share public offerings, and Beyang Therapeutics and Remepy closed $30+ million oversubscribed Series A rounds.

Second quarter 2026 net product revenue of $18.6 million; cash and cash equivalents of $219.1 million as of June 30, 2026

Beyang Therapeutics has raised nearly $30 million in an oversubscribed Series A financing round to advance its AI-powered drug discovery platform and clinical pipeline.

Welcome to our dedicated page for Attovia Therapeutics SEC filings (Ticker: ATTO), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Celldex Therapeutics, Inc. recently reported second-quarter 2026 results, with revenue falling to US$0.022 million and net loss widening to US$73.5 million, while loss per share from continuing operations increased to US$0.94.

Non-dilutive funding will support the commercialization, development, and expansion strategy for Sonire’s Ultrasound-Guided HIFU Platform

Aug. 7, 2026 /PRNewswire/ — Atossa Therapeutics, Inc. (Nasdaq: ATOS) (Atossa or the Company), a clinical-stage biopharmaceutical company developing novel therapies in oncology and other areas of high unmet clinical need, today announced its financial results and provided an update on recent corporate developments for the second quarter ended June 30, 2026

Phase 1 trials for HWK-007 and HWK-016 continue to enroll; the Phase 1 trial for HWK-206 is on track to initiate in Q3 2026